Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing promising results in addressing excess mass and related 2 disease. Initial data suggest a unique mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/